Skip to main content

Table 1 Daytime and nighttime HR changes (bpm)

From: Differential effects of glucagon-like peptide-1 receptor agonists on heart rate

Daytime

Lixisenatide 20 μg (n = 40)

Liraglutide 1.2 mg (n = 40)

Liraglutide 1.8 mg (n = 41)

At baseline

71.0

69.3

70.0

At week 8

74.7

79.3

79.4

LS mean (SE) change from baseline

3.67 (1.42)

9.41 (1.31)

9.10 (1.38)

LS mean (SE) difference vs. lixisenatide

 

5.74 (1.23)

5.43 (1.20)

Difference vs. lixisenatide: p value

 

<0.0001

<0.0001

Nighttime

Lixisenatide 20 μg (n = 42)

Liraglutide 1.2 mg (n = 43)

Liraglutide 1.8 mg (n = 44)

At baseline

67.1

65.1

66.2

At Week 8

69.7

75.7

76.7

LS mean (SE) change from baseline

2.20 (1.47)

9.97 (1.37)

10.12 (1.45)

LS mean (SE) difference vs. lixisenatide

 

7.78 (1.26)

7.92 (1.24)

Difference vs. lixisenatide: p value

 

<0.0001

<0.0001

  1. Daytime and nighttime HR changes (bpm) following 8 weeks’ treatment with lixisenatide vs. liraglutide in subjects with T2DM are shown. Please note that n numbers are for the number of patients for whom HR data were available
  2. bpm beats per minute, HR heart rate, LS least squares, SE standard error, T2DM type 2 diabetes mellitus
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840